These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3119364)

  • 1. Ixodes dammini: salivary anti-complement activity.
    Ribeiro JM
    Exp Parasitol; 1987 Dec; 64(3):347-53. PubMed ID: 3119364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    Medof ME; Kinoshita T; Nussenzweig V
    J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A low molecular weight inhibitor of the alternative complement pathway. I. Its isolation from human urine and the reaction mechanism.
    Nagaki K; Matsumoto M; Kitamura H
    Immunology; 1980 Dec; 41(4):789-98. PubMed ID: 6450726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the mechanisms of anti-complement activity in Ixodes ricinus ticks.
    Lawrie CH; Sim RB; Nuttall PA
    Mol Immunol; 2005 Jan; 42(1):31-8. PubMed ID: 15488941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihemostatic, antiinflammatory, and immunosuppressive properties of the saliva of a tick, Ixodes dammini.
    Ribeiro JM; Makoul GT; Levine J; Robinson DR; Spielman A
    J Exp Med; 1985 Feb; 161(2):332-44. PubMed ID: 2982989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Homeostasis of the complement system--complement inhibitors].
    Nagaki K
    Nihon Rinsho; 1979 May; 37(5):969-76. PubMed ID: 381728
    [No Abstract]   [Full Text] [Related]  

  • 7. A novel mechanism of complement inhibition unmasked by a tick salivary protein that binds to properdin.
    Tyson KR; Elkins C; de Silva AM
    J Immunol; 2008 Mar; 180(6):3964-8. PubMed ID: 18322205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and characterization of a low molecular weight complement inhibitor present in normal human serum.
    Baker PJ; Osofsky SG
    Clin Exp Immunol; 1981 Mar; 43(3):549-56. PubMed ID: 6912799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
    Medicus RG; Melamed J; Arnaout MA
    Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of granulocyte histaminase release by particle-bound complement C3 cleavage products (C3b, C3bi) and IgG.
    Melamed J; Medicus RG; Arnaout MA; Colten HR
    J Immunol; 1983 Jul; 131(1):439-44. PubMed ID: 6223078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b.
    Sahu A; Rawal N; Pangburn MK
    Biochem Pharmacol; 1999 Jun; 57(12):1439-46. PubMed ID: 10353266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-covalently bound C3 enhances lysis of rabbit erythrocytes through the alternative pathway.
    Hidvégi T; Füst G; Rajnavölgyi E; Kulics J; Gergely J
    Immunology; 1985 Dec; 56(4):735-41. PubMed ID: 3935572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human and mouse complement-dependent hemolytic activity by mouse fibronectin.
    Hitsumoto Y; Okada M; Makino H
    Immunopharmacology; 1999 May; 42(1-3):203-8. PubMed ID: 10408381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA).
    Feuillard J; Maillet F; Goldschmidt P; Weiss L; Kazatchkine MD
    Agents Actions; 1991 Mar; 32(3-4):343-6. PubMed ID: 1862751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A molecular basis of activation of the alternative pathway of human complement.
    Austen KF; Fearon DT
    Adv Exp Med Biol; 1979; 120B():3-17. PubMed ID: 390986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b).
    Gitlin JD; Rosen FS; Lachmann PJ
    J Exp Med; 1975 May; 141(5):1221-6. PubMed ID: 1168693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saliva of Rhipicephalus (Boophilus) microplus (Acari: Ixodidae) inhibits classical and alternative complement pathways.
    Silva NC; Vale VF; Franco PF; Gontijo NF; Valenzuela JG; Pereira MH; Sant'Anna MR; Rodrigues DS; Lima WS; Fux B; Araujo RN
    Parasit Vectors; 2016 Aug; 9(1):445. PubMed ID: 27515662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and characterization of rabbit H of the alternative complement pathway.
    Nakano Y; Tobe T; Matsuda T; Sakamoto T; Tomita M
    J Biochem; 1984 May; 95(5):1469-75. PubMed ID: 6746616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.